Abstract:Aims: Circulating levels of sphingosine 1-phosphate (S1P), an HDL-associated ligand for endothelial cell (EC) protective S1P receptor-1 (S1PR1), are reduced in disease states associated with endothelial dysfunction. Yet as S1PR1 has high affinity for S1P and can be activated by ligand-independent mechanisms and EC-autonomous S1P production, it is unclear if relative reductions in circulating S1P impact endothelial function. It is also unclear how EC S1PR1 insufficiency, whether induced by ligand deficiency or by S1PR1-directed immunosuppressive therapy, affects different vascular subsets. Methods and results: We here fine-map the zonation of S1PR1 signalling in the murine blood and lymphatic vasculature, superimpose cell type-specific and relative deficiencies in S1P production to define ligand source- and dose-dependence, and correlate receptor engagement to essential functions. In naïve blood vessels, despite broad expression, EC S1PR1 engagement was restricted to resistance-size arteries, lung capillaries and high-endothelial venules (HEV). Similar zonation was observed for albumin extravasation in EC S1PR1 deficient mice, and brain extravasation was reproduced with arterial EC-selective S1pr1 deletion. In lymphatic EC, S1PR1 engagement was high in collecting vessels and lymph nodes and low in terminal capillaries that drain tissue fluids. While EC S1P production sustained S1PR1 signaling in lymphatics and HEV, hematopoietic cells provided ∼90% of plasma S1P and sustained signaling in resistance arteries and lung capillaries. S1PR1 signaling and endothelial function were both surprisingly sensitive to reductions in plasma S1P with apparent saturation around 50% of normal levels. S1PR1 engagement did not depend on sex or age, but modestly increased in arteries in hypertension and diabetes. Sphingosine kinase (Sphk)-2 deficiency also increased S1PR1 engagement selectively in arteries, which could be attributed to Sphk1-dependent S1P release from perivascular macrophages. Conclusions: This study highlights vessel subtype-specific S1PR1 functions and mechanisms of engagement and supports the relevance of S1P as circulating biomarker for endothelial function.

Point-Counterpoint of Sphingosine 1-Phosphate Metabolism

Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.

Sphingosine 1-phosphate and inflammation.

Sphingosine 1-phosphate: Lipid signaling in pathology and therapy

Sphingosine 1-phosphate, a key mediator of the cytokine network: juxtacrine signaling.

Modulation of protein kinase C and diverse cell functions by sphingosine--a pharmacologically interesting compound linking sphingolipids and signal transduction

Sphingosine-1-phosphate Signaling Pathway: a Novel Therapeutic Target for Cardiovascular Diseases

An overview of sphingosine‐1‐phosphate receptor 2: Structure, biological function, and small‐molecule modulators

Sphingosine 1-phosphate and its regulatory role in vascular endothelial cells

Sphingosine 1-phosphate in blood: function, metabolism, and fate

Sphingosine‐1‐phosphate receptors and innate immunity

Molecular basis of Spns2-facilitated sphingosine-1-phosphate transport

Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases

Insight into modulators of sphingosine-1-phosphate receptor and implications for cardiovascular therapeutics

Sphingolipids and their metabolism in physiology and disease

020 Regulation of Sphingosine-1-Phosphate (S1P) Signaling Pathway in Rats and Humans and Alterations in Response to Pathologically-Induced Erectile Dysfunction

Atypical sphingosine-1-phosphate metabolites-biological implications of alkyl chain length

Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology

Abstract P212: Sphingolipid De Novo Pathway is a Novel Regulator of Blood Pressure Homeostasis

Principles of bioactive lipid signalling: lessons from sphingolipids

Zonation, ligand and dose dependence of S1PR1 signalling in blood and lymphatic vasculature